Fredun Pharmaceuticals Ltd

Company Profile

Fredun Pharmaceuticals Ltd had its IPO on under the ticker symbol FREDUN.

The company operates in the sector and industry. Fredun Pharmaceuticals Ltd has a staff strength of 0 employees.

Stock update

Shares of Fredun Pharmaceuticals Ltd opened at ₹899.95 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹860 - ₹910, and closed at ₹881.15.

This is a -2.61% slip from the previous day's closing price.

A total volume of 4,320 shares were traded at the close of the day’s session.

In the last one week, shares of Fredun Pharmaceuticals Ltd have slipped by -10.09%.

Fredun Pharmaceuticals Ltd's Key Ratios

Fredun Pharmaceuticals Ltd has a market cap of ₹4.05 billion, indicating a price to book ratio of 7.6226 and a price to sales ratio of 2.9376.

In the last 12-months Fredun Pharmaceuticals Ltd’s revenue was ₹0 with a gross profit of ₹254.78 million and an EBITDA of ₹0. The EBITDA ratio measures Fredun Pharmaceuticals Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Fredun Pharmaceuticals Ltd’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 1392.02%.

In Q2, Fredun Pharmaceuticals Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Fredun Pharmaceuticals Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

212.9222

PEG

Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fredun Pharmaceuticals Ltd’s profitability.

Fredun Pharmaceuticals Ltd stock is trading at a EV to sales ratio of 2.5691 and a EV to EBITDA ratio of 30.5583. Its price to sales ratio in the trailing 12-months stood at 2.9376.

Fredun Pharmaceuticals Ltd stock pays annual dividends of ₹0.66 per share, indicating a yield of 0.07% and a payout ratio of 3.5%.

Balance sheet and cash flow metrics

Total Assets

₹2.57 billion

Total Liabilities

₹1.06 billion

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

3.5%

Fredun Pharmaceuticals Ltd ended 2024 with ₹2.57 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹2.57 billion while shareholder equity stood at ₹963.76 million.

Fredun Pharmaceuticals Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹1.06 billion in other current liabilities, 45323000.00 in common stock, ₹918.44 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹4.89 million and cash and short-term investments were ₹162.50 million. The company’s total short-term debt was ₹375,962,000 while long-term debt stood at ₹489.29 million.

Fredun Pharmaceuticals Ltd’s total current assets stands at ₹2.16 billion while long-term investments were ₹0 and short-term investments were ₹128.15 million. Its net receivables were ₹345.60 million compared to accounts payable of ₹6000.00 and inventory worth ₹1.50 billion.

In 2024, Fredun Pharmaceuticals Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Fredun Pharmaceuticals Ltd paid ₹0.04 in dividends in 2024.

Other key metrics

Current Trading Price

₹881.15

52-Week High

₹1428

52-Week Low

₹740

Analyst Target Price

₹

Fredun Pharmaceuticals Ltd stock is currently trading at ₹881.15 per share. It touched a 52-week high of ₹1428 and a 52-week low of ₹1428. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹945.6 and 200-day moving average was ₹966.14 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.